ASTM F2260-03 - 10.4.2003
 
1. Scope

1.1 This test method covers the determination of the degree of deacetylation in chitosan and chitosan salts intended for use in biomedical and pharmaceutical applications as well as in Tissue Engineered Medical Products (TEMPs) by high-resolution proton NMR (1H NMR). A guide for the characterization of chitosan salts has been published as Guide F 2103.

1.2 The test method is applicable for determining the degree of deacetylation (% DA) of chitosan chloride and chitosan glutamate salts and is valid for % DA values from 50 up to and including 99. It is simple, rapid, and suitable for routine use. Knowledge of the degree of deacetylation is important for an understanding of the functionality of chitosan salts in TEMP formulations and applications. This test method will assist end users in choosing the correct chitosan for their particular application. Chitosan salts may have utility in drug delivery applications, as a scaffold or matrix material, and in cell and tissue encapsulation applications.

1.3 This standard does not purport to address all of the safety concerns, if any, associated with its use. It is the responsibility of the user of this standard to establish appropriate safety and health practices and determine the applicability of regulatory limitations prior to use.

 
2. Referenced Documents

European Pharmacopoeia Monograph 2008:1774

Chitosan Chloride Available from European Directorate for the Quality of Medicines (EDQM), Publications and Services, European Pharmacopoeia, BP 907, F-67029 Strasbourg, France.

F386-17(2022)

Standard Test Method for Thickness of Resilient Flooring Materials Having Flat Surfaces

F2103-18

Standard Guide for Characterization and Testing of Chitosan Salts as Starting Materials Intended for Use in Biomedical and Tissue-Engineered Medical Product Applications

USP 35-NF30 <761>

Nuclear Magnetic Resonance Available from U.S. Pharmacopeia (USP), 12601 Twinbrook Pkwy., Rockville, MD 20852-1790, http://www.usp.org.